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Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect that can be very disabling and can limit or delay
the dose of chemotherapy that can be administered. Acupuncture may be effective for treating peripheral neuropathy. The aim of
this study was to review the available literature on the use of acupuncture for CIPN.The systematic literature search was performed
using MEDLINE, Google Scholar, Cochrane Database, CINHAL, and ISI Proceedings. Hand searching was conducted, and
consensus was reached on all extracted data. Only papers in the English language were included, irrespective of study design. From
3989 retrieved papers, 8 relevant papers were identified. One was an experimental study which showed that electroacupuncture
suppressed CIPN pain in rats. In addition, there were 7 very heterogeneous clinical studies, 1 controlled randomised study using
auricular acupuncture, 2 randomized controlled studies using somatic acupuncture, and 3 case series/case reports which suggested
a positive effect of acupuncture in CIPN. Conclusions. Only one controlled randomised study demonstrated that acupuncture may
be beneficial for CIPN. All the clinical studies reviewed had important methodological limitations. Further studies with robust
methodology are needed to demonstrate the role of acupuncture for treating CIPN resulting from cancer treatment.
1. Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a
common side effect after patient exposure to chemotherapy
agents such as vinca alkaloids, platinum derivatives, and
taxanes and to newer agents such as bortezomib and thalido-
mide. CIPN is the second most important side effect in
frequency after hematologic toxicity and can limit or delay the
dose of chemotherapy that can be administered [1]. Sensory,
motor, and/or autonomic neurotoxicity can be very disabling
and/or painful, creating a major impact on patients’ quality
of life and adherence to treatment.
Conventionally, CIPN is prevented with the use of intra-
venous calcium andmagnesium, without reducing treatment
response. Pharmacological treatment of other CIPN symp-
toms like numbness or palsies is not usually effective, but
there are some other options for treatment of neuropathic
pain such as the use of antiepileptic and tricyclic antidepres-
sant drugs (e.g., carbamazepine, lamotrigine, gabapentine or
pregabalin, and venflaxine). There is no established pharma-
cological treatment for neuroregeneration [2, 3].
The mechanism of neurotoxicity of the antineoplastic
agents is unclear. CIPN generally arises as a consequence of
the disruption of axoplasmic microtubule mediated trans-
port, distal axonal degeneration, and direct damage to
the sensory nerve cell bodies of the dorsal root ganglia
(DRG). Mitochondrial damage in the DRG neuron has been
described as well [4]. The DRG neurons lack a vascular
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barrier, in contrast to those in the central nervous system, and
aremore exposed to the neurotoxic effects of the antineoplas-
tic agents. Both central and peripheral mechanisms seem to
be involved.
Acupuncture stimulates areas of the skin using different
methods including the insertion of thin needles that are
then manipulated manually or electrically. In animal models
acupuncture has been shown to reduce neuropathic pain in a
variety of experimental conditions. Cold allodynia has been
reduced in rats treated with electroacupuncture through the
mediation of spinal alfa2-adrenergic receptors [5], while in
mechanical allodynia electroacupuncture has been shown to
act through mu and delta but not kappa opioid receptors
[6]. Another possible effect of electroacupuncture in an
experimental model of neuropathy may be the inhibition
of COX2 expression [7]. It has been shown that elec-
troacupuncture at the acupoint Zusanli (ST36) reduced the
mechanical allodynia in a neuropathic model, normalising
the expression profile of hypothalamic proteins, that have
been mainly identified as being involved in inflammatory
processes, metabolism and signal transduction [8]. Ko and
colleagues [9] examined the mechanism of neuropathic pain
and the analgesic effects of acupuncture at the molecular
level by cDNA microarray analysis. They observed that the
expression of 68 genes had more than doubled in a model
of neuropathic pain in the rat but returned to normal
after treatment with electroacupuncture. The genes were
involved in biological processes such as signal translation,
gene expression, and nociceptive pathways [9]. Also the
expression of the sigma opioid receptorwas decreased by 50%
in the neuropathic pain model and was returned to normal
after acupuncture. This could explain the poor response
of neuropathic pain to the treatment with opioids, since
the opioid receptor is downregulated in this condition, and
could partially explain the analgesic action of acupuncture
in neuropathic pain, because acupuncture normalises the
opioid receptor expression and also increases the release of
endogenous opioid peptides.
Cancer patients often seek additional help for their
disease or for treatment-related side effects. A European
survey in 13 countries [10] showed a prevalence of 35.9% of
complementary therapy use (range among countries 14.8%
to 73.1%). Acupuncture was used by 3.9% patients before
cancer diagnosis and by 3% patients after cancer diagno-
sis. Acupuncture has also been shown to be effective for
chemotherapy induced nausea and vomiting [11], xerostomia
induced by radiation therapy [12, 13], fatigue [14], anxiety,
depression, and insomnia [15]. Furthermore, acupuncture
has been used encouragingly to treat peripheral neuropathy
associated with diabetes and HIV [16–22].
In this paper the existing evidence of acupuncture effec-
tiveness and/or efficacy for CIPN has been systematically
reviewed.
2. Methodology
To review the existing clinical and experimental studies of
acupuncture in CIPN, the systematic literature search was
performed from the databases inception up until January
2012 using MEDLINE, Google Scholar, Cochrane Database,
CINHAL (Cumulative Index to Nursing and Allied Health
Literature), CNKI (China National Knowledge Infrastruc-
ture), Wanfang Med Online, and ISI Proceedings for confer-
ence abstracts. The keywords searched were (acupoint∗ OR
acupuncture OR electro-acupuncture OR electroacupunc-
ture OR moxibustion) AND “peripheral neuropathy.” The
CINHAL, CNKI, and Wanfang Med Online Databases did
not allow logical searches with AND, so we used simple
combinations of the search words. Historical searches of
reference lists of relevant articles were also undertaken. To
be included in the review, a study had to explore either the
efficacy or the effectiveness of acupuncture needling forCIPN
in either human or animal models irrespective of design. All
papers with at least an abstract in English were included.
Study selection was performed by two reviewers (Giovanna
Franconi and Luigi Manni) with disagreement resolved by
discussion and adjudication.
3. Results
A total of 3989 articles were retrieved from electronic
searches and subsequent examination of reference lists of
the clinical and review articles. After screening titles and/or
abstracts, 3891 articles were excluded for the following rea-
sons: the focus was on an intervention other than acupunc-
ture, the neuropathy was not related to chemotherapy, the
acupuncture treatment plan included additional interven-
tions/modalities that were not acupuncture related, there
were duplicated studies, or they were not relevant. From
a total of 98 articles which were retrieved for detailed
evaluation, 7 clinical studies and 1 experimental study were
included in the review. For a summary of the clinical studies
see Table 1.
Only one study was identified that addressed the topic
of electroacupuncture (EA) and its effects on CIPN in an
animal model. Meng and colleagues [30] demonstrated that
EA at both low (10Hz) and high (100Hz) frequencies was able
to improve neuropathic pain in paclitaxel-treated rats. The
authors reported that low-frequency EA was more effective
than high-frequency EA in relieving neuropathic symptoms
and that opioid receptors antagonists (all types) abolished EA
effects. It is known that low-frequency (2–15Hz) EA engages
centrally mediated endorphin, enkephalin, serotonergic, and
noradrenergic analgesia, while high frequency EA (100Hz)
engages segmental-spinal opioids (dynorphin, enkephalin)
and nonopioid (gamma aminobutyric acid, glycine) analgesia
[31]. Thus it is conceivable that central-mediated effects of
acupuncture are involved in suppression of neuropathic pain
in CIPN.
For a summary of the clinical studies see Table 1.
Thefirst published clinical study that explored the efficacy
of acupuncture in cancer pain used auricular acupuncture in
a population of 90 patients with neuropathic pain (despite
stable medication) [23]. A small minority of patients also
presented nociceptive pain. The patients were randomly
divided into 3 arms: one arm with steel implants on auricular
points eliciting an electrical response and 2 placebo armswith
either steel implants or vaccaria seeds on auricular points
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Table 1: Characteristics of the studies involving the use of acupuncture in CIPN.
Authors Patients (𝑛) Design of the study Intervention andcontrol
Duration of
intervention Outcome(s) Results
Alimi et al.,
2003 [23] 90
Prospective
randomized
controlled trial
Auricular
acupuncture versus
placebo acupuncture
and seeds
2 months
VAS pain score and
medication
consumption
True acupuncture
better than placebo
Wong and
Sagar, 2006
[24]
5 Prospective caseseries
Acupuncture (no
control)
16 weeks
(Two 6-week
courses with a
4-week therapy
free interval)
Pain score and WHO
CIPN grade Improvement
Xu et al., 2010
[25] 64
Controlled
randomized trial
Acupuncture versus
cobamamide Not known
Questionnaire of
peripheral
neuropathy
Acupuncture better
that cobamamide
Bao et al., 2011
[26] 1 Case report
Acupuncture (no
control) 22 weeks VAS pain score No more symptoms
Donald et al.,
2011 [27] 18
Retrospective case
series
Acupuncture (no
control) 6 weeks Subjective symptoms 82% improved
Schroeder et al.,
2012 [28] 11
Retrospective
controlled
nonrandomized
trial
Acupuncture and best
medical care versus
best medical care
10 weeks Nerve conductionstudies
Acupuncture better
than control
Tian et al., 2011
[29] 76
Controlled
randomized trial
Warm acupuncture
and moxibustion
versus Neurotropin
Not known Quality of life andneurotoxic symptoms
Acupuncture better
than Neurotropin
Legend: VAS: visual analog scale; FACT-G: Functional Assessment of Cancer Therapy-General.
not eliciting an electrical response. Patients were treated for
2 one-month cycles. After 2 months the pain VAS score was
significantly decreased in the true acupuncture group, while
there was no effect of placebo.
In one prospective case series 5 patients were treated
with manual acupuncture for their chemotherapy-induced
neuropathy [24]. Acupuncture was performed once a week
according to TCM diagnosis using acupoints CV6 (Qihai),
ST36 (Zusanli), LI11 (Quchi), EX-LE10 (Bafeng), and EX-
UE9 (Baxie) for two 6-week cycles, separated by 4 weeks. All
patients showed an improvement in pain score and on the
WHO grade of neuropathy after treatment with acupuncture.
There were no observed side effects, and benefits persisted for
6 months of followup in 4/5 patients.
Xu et al. [25] studied 64 patients with CIPN induced
by paclitaxel or oxaliplatin. The patients were randomized
to an acupuncture group or a control group treated with
cobamamide. The acupuncture treatment included points
such as Hegu (LI4), Taichong (LR3), Zusanli (ST36), Qihai
(CV6), and Quchi (LI11) and was performed for an unspec-
ified length of time. The outcome was an evaluation of
neurotoxicity assessed by a CIPN questionnaire. The twenty
patients in the acupuncture group significantly improved,
compared to the 12 patients in the control group.
A case report [26] described one patient with multiple
myeloma and bortezomib-induced CIPN who was treated
with 6 weekly sessions of acupuncture, followed by sub-
sequent 8 sessions over the next 5.5 months. The treat-
ment protocol included body acupuncture at LI4 (Hegu),
TE5 (Waiguan), LI11 (Quchi), ST40 (Fenglong), EX-LE10
(Bafeng), and auricular acupuncture at shenmen, point zero,
and 2 additional points were stimulated electrically. The VAS
pain score decreased from 8/10 to 2/10 after 6 treatments, and
the pain medication with morphine sulphate and oxycodone
was stopped after 14 treatments. The patient remained pain-
free for at least one year. There were no observed side
effects.
A retrospective case series examined 18 patients affected
by CIPN [27]. Patients were treated by 6 weekly acupuncture
sessions, with acupoints selected on the basis of patient
presentation at each session. No validated questionnaires
were used, and side effects were not recorded. The most
commonly used points were SP6 (Sanyinjiao) and ST36
(Zusanli), followed by LV3 (Taichong). After 6 weeks 82%
(𝑛 = 14) patients reported an improvement of their neurop-
athy symptoms, 18% (𝑛 = 3) reported no change.
In a pilot controlled nonrandomised study [28], 6 patients
with CIPN accepted acupuncture treatment, and 5 patients
with CIPNwho had refused acupuncture treatment served as
controls. All patients received the best medical care, and the
6 patients in the acupuncture group were also treated with 10
weekly acupuncture treatments with a fixed protocol (ST34
Liangqiu, EX-LE12 Qiduan, and EX-LE10 Bafeng bilaterally).
Nerve conduction studies (NCS) were done to confirm the
presence of CIPN at baseline and 6 months later, that is, 3
months after the end of acupuncture treatment. Acupuncture
significantly improved nerve conduction velocity and mean
amplitude of NCS in treated patients, while there was no
difference after the same time in the control group.Therewere
no observed side effects.
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The last study included in this review was a randomized
controlled trial of 76 patients with gastrointestinal cancer
and CIPN induced by oxaliplatin [29]. The intervention
group received warm acupuncture and moxibustion, and
the control group was treated with Neurotropin 4mg given
intramuscularly every day for 21 days. The intervention
receiving acupuncture and moxibustion reported a signifi-
cantly improved quality of life and reduction in neurotoxic
symptoms.
4. Discussion
Complementary therapies in cancer care are used primarily to
treat the symptoms associated with cancer and its treatments.
This review suggests that although there are some indications
that acupuncture may be effective in improving symptoms
and neural damage associated with CIPN, the current evi-
dence available is limited.
The positive effects of acupuncture in CIPN consist
in a reduction in the pain score in most studies. Pain
is the most common and the best studied indication for
acupuncture, and acupuncture has been recommended as
a complementary therapy for pain control or for reducing
the amount of pain medicine in cancer patients. According
to the evidence-based guidelines of the American College
of Chest Physicians for lung cancer [32], acupuncture is
recommended as a complementary therapy for lung cancer
when pain is poorly controlled or when side effects such as
neuropathy or xerostomia are clinically significant (grade 1A
recommendation). The rationale is based on the analgesic
action of acupuncture in acute and chronic pain and in cancer
pain. Furthermore, studies on pain using functionalmagnetic
resonance (fMRI) showed that acupuncture could modulate
the cognitive-affective aspects of pain perception [33].
Improvement was also reported for other symptoms of
CIPN in the paper by Wong and Sagar [24], where the
effects of acupuncture were measured by the WHO CIPN
score, which takes into account both the sensory and motor
abnormalities of CIPN. One study [28] evaluated acupunc-
ture effects with nerve conduction studies, which allowed
a separate measurement of motor and sensory signals and
showed a significant positive effect of acupuncture on motor
and sensory parameters.
The studies included in this systematic review were very
heterogeneous: 3 studies [23, 25, 29] were prospective ran-
domized controlled trials, while another [28] was a retrospec-
tive analysis of a controlled study. These controlled studies
showed a specific effect of acupuncture, unrelated to skin
penetration. The remaining studies were uncontrolled case
reports or case series. Such uncontrolled studies may present
bias and lead to false positive results. The issue of choosing
a control in acupuncture research is not a simple one, as
placebo/sham acupuncture shares many pathways with true
acupuncture (i.e., activation of opioid system as well as other
pain-controlling neurotransmitters systems and activation of
cerebral areas on fMRI), and the placebo/sham acupuncture
used in acupuncture studies is not necessarily inert [34–37].
Different protocols were utilized to treat CIPN: auricular
acupuncture only, and somatic acupuncture only, combined
auricular and body acupuncture, each applied on different
combinations of acupoints. Acupuncture protocols are usu-
ally standardized in acupuncture research, but this may not
reflect what clinical acupuncturists do every day in their
clinics, as acupuncture in TCM is a very individualized
medicine [38]. Furthermore the choice of acupuncture points
in a protocol depends on the reference system, which com-
prises many different schools and different approaches to
acupuncture, such as acupuncture according to traditional
Chinese medicine, medical acupuncture, Japanese acupunc-
ture, French auricular acupuncture, trigger-point acupunc-
ture, acupressure, electroacupuncture, and transcutaneous
electrical nerve stimulation (TENS) of acupuncture points,
among others [39], each one with a different approach to
comparable problems. Future studies with sufficient number
of patients should also address the issue of whether a prag-
matic approach or a protocol approach should be employed.
Heterogeneity was also present when considering the
outcome measurements, which ranged from subjective eval-
uation to pain VAS score to nerve conduction studies (NCS),
which make it impossible to compare studies. More objective
outcome measurements are advisable, and among them
NCS which measures the number and conduction velocities
of large myelinated fibers and relates to both the clinical
subjective improvement and the histological nerve healing.
Neuronal damage by antineoplastic agents probably acti-
vates second messenger systems which cause hyperalgesia,
allodynia, and pain, because it may be relieved by supple-
mentation with trophic factors such as NGF, insulin growth
factor 1 (IGF-1), and neurotrophin 3 (NT-3) [40]. There is a
large experimental evidence base on the involvement of NGF
in CIPN [41–44]. NGF promotes physiological maturation,
survival, and expression of the specific phenotype in primary
sensory neurons located in the DRG [45]. Acupuncture
analgesia is an effect that has been amply demonstrated
and occurs via the activation of different systems, involving
nerves, hormones, cytokines, and other mediators [46].
At a neuroendocrine level acupuncture modulates various
neurotrophins and growth factors including NGF [47], glial-
derived neurotrophic factor (GDNF) [48–50], brain-derived
neurotrophic factor (BDNF) [51, 52], and insulin growth
factor (IGF) [53]. It is possible that the action of acupunc-
ture on neuropathic pain be mediated by enhancement of
spinal/central GABA-ergic, serotoninergic, and adrenergic
neurotransmission [54–58] as well as by the action of
acupuncture on the NGF system, driving NGF signalling
toward its downregulation with parallel decrease in sen-
sory neurons hypersensitization [59]. Thus, acupuncture can
modify the expression of different genes and the expression
of genes that control transcriptional factors that are crucial
for cell homeostasis [60]. In Figure 1, we summarized the
acupuncture mechanisms and mediators in CIPN based on
what we know from animal studies of diabetic neuropathy
[59, 61] and from human studies of brain imaging during
acupuncture [62].
It is interesting to note that all the studies which used
somatic acupuncture and described their protocol [24, 26–
28] employed local points. EX-LE10 (Bafeng) is 4 points
on the instep of each foot, proximal to the margin of
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Periphery
Afferent nerve activation.
Induction of NGF synthesis.
Downregulation of inflammatory 
cytokines.
Spinal cord
Blockade of painful stimuli by 
opioids and GABA activation.
Regulation of autonomic activity. 
Improved blood flow to peripheral 
organs.
Brainstem
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Thalamus
Limbic system
Cortex
Descending modulation of pain.
Regulation of autonomic activity. 
Possible effects on higher brain 
functions (mood, depression, and anxiety).
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effects of acupuncture in 
CIPN patients
Nervous system areas 
activated by acupuncture
Figure 1: Possible targets of acupuncture treatment in CIPN.On the left side are the nervous system areas which are activated by acupuncture;
on the right side are some possible beneficial effects of acupuncture in CIPN patients. CIPN = chemotherapy-induced peripheral neuropathy;
GABA = gamma amino butyric acid; NGF = nerve growth factor.
the webs between each two neighbouring toes, while EX-
UE9 (Baxie) is 4 points proximal to the margin of the
webs between each two of the five fingers of a hand. The
rationale behind the choice of points located nearby or in
the same dermatome of the affected limb/region might lie in
the activation of spinal response after acupuncture. Indeed
thewestern neurophysiological hypothesis on themechanism
of acupuncture efficacy proposes that needle insertion and
stimulation elicits a three-level response: local (at the site of
needling) that could encompass the so called “flare reaction”;
segmental, that includes all the acupuncture-induced reflex
variations in spinal neurotransmission, that is, GABA-ergic
one; central, that refers to the overall variation induced by
needle stimulation in the activity and feedback response in
the brain [35].Thus, it is possible to link the positive outcome
in such studies to the spinal/segmental activation of opioids
and/or GABA signalling, in accordance with previous results
on animal models [30].
The limitations of the studies reviewed include the small
sample size of most studies, the presence of poor controls
or no controls, poor randomization, and lack of blinding.
However, the presence of some studies of good quality which
suggest a positive effect of acupuncture in CIPN support the
planning of more rigorous randomised controlled clinical
studies evaluating the efficacy of acupuncture in CIPN. The
advantages of acupuncture are its safety and low cost, and it
would be very important to demonstrate its efficacy in such
a disabling and potentially dangerous side effect of cancer
treatment such as CIPN.
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